DexCom, Inc. (NASDAQ:DXCM) Director Sells $24,756.16 in Stock

DexCom, Inc. (NASDAQ:DXCM - Get Free Report) Director Bridgette P. Heller sold 352 shares of the company's stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $70.33, for a total value of $24,756.16. Following the transaction, the director now owns 22,997 shares of the company's stock, valued at approximately $1,617,379.01. This represents a 1.51 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

DexCom Stock Down 1.7 %

NASDAQ:DXCM traded down $1.31 on Friday, reaching $73.80. 5,560,851 shares of the stock traded hands, compared to its average volume of 3,922,409. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. The company has a market capitalization of $28.84 billion, a price-to-earnings ratio of 51.61, a PEG ratio of 2.30 and a beta of 1.28. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00. The company's fifty day simple moving average is $83.33 and its 200 day simple moving average is $76.98.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Equities analysts predict that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Remove Ads

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Jennison Associates LLC raised its position in DexCom by 1,683.2% in the 3rd quarter. Jennison Associates LLC now owns 6,932,899 shares of the medical device company's stock worth $464,782,000 after buying an additional 6,544,102 shares during the last quarter. Norges Bank bought a new stake in shares of DexCom in the fourth quarter worth approximately $385,367,000. Congress Asset Management Co. raised its holdings in shares of DexCom by 5,456.9% during the fourth quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company's stock valued at $105,529,000 after purchasing an additional 1,332,522 shares during the last quarter. Fisher Funds Management LTD purchased a new position in shares of DexCom during the fourth quarter valued at approximately $96,507,000. Finally, Westfield Capital Management Co. LP lifted its position in DexCom by 44.6% during the third quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company's stock valued at $190,532,000 after purchasing an additional 876,739 shares during the period. Hedge funds and other institutional investors own 97.75% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the stock. Wells Fargo & Company reaffirmed an "overweight" rating on shares of DexCom in a research note on Saturday, March 8th. Baird R W raised DexCom from a "hold" rating to a "strong-buy" rating in a research report on Thursday, January 16th. Canaccord Genuity Group increased their target price on DexCom from $99.00 to $103.00 and gave the stock a "buy" rating in a research report on Friday, February 14th. Morgan Stanley lifted their price target on DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a research report on Friday, February 14th. Finally, Citigroup upped their price target on DexCom from $101.00 to $104.00 and gave the stock a "buy" rating in a research note on Tuesday, March 4th. Four analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $99.82.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.